Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.5%

1 terminated/withdrawn out of 22 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

41%

9 trials in Phase 3/4

Results Transparency

0%

0 of 13 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
9(50.0%)
Phase 1
7(38.9%)
N/A
1(5.6%)
Phase 2
1(5.6%)
18Total
Phase 3(9)
Phase 1(7)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT07096050Not ApplicableCompleted

Post Marketing Clinical Follow up Study of HyaleXo

Role: lead

NCT04368507Phase 1Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

Role: collaborator

NCT05226897Phase 3Unknown

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Role: lead

NCT05362851Phase 3Unknown

Clinical Trial of YYC301 P3 for Treatment of Osteoarthritis of the Knee

Role: lead

NCT05348525Unknown

Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of ORTHIX PLUS

Role: lead

NCT05229458Unknown

Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of HYALEXO

Role: lead

NCT03943992Phase 3Completed

Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)

Role: lead

NCT03555123Phase 3Unknown

Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX

Role: lead

NCT03985319Phase 1Completed

Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)

Role: lead

NCT03850587Phase 2Completed

Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee

Role: lead

NCT03967886Phase 3Completed

Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

Role: lead

NCT03561779Phase 3Completed

Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee

Role: lead

NCT03170050Phase 3Completed

Clinical Trial of YYD701-2 for Treatment of Nasolabial Folds

Role: lead

NCT04874129Phase 1Unknown

Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

Role: lead

NCT04874142Phase 1Completed

Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A

Role: lead

NCT04858308Phase 3Unknown

Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.

Role: lead

NCT02166593Phase 3Completed

Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin

Role: lead

NCT03558477Phase 1Completed

PK/PD Clinical Trial of YYD601 in Healthy Adult Male

Role: lead

NCT02965495Phase 1Completed

Clinical Trial of YYD302 for Treatment of Osteoarthritis of the Knee

Role: lead

NCT03214211Unknown

Prospective Observational Study of Pravafenix Cap

Role: lead